Search

Your search keyword '"Aránzazu Montilla Bernabé"' showing total 2 results
Start Over Author "Aránzazu Montilla Bernabé"
2 results on '"Aránzazu Montilla Bernabé"'

1. A randomized, double-blind study on the efficacy of oral domperidone versus placebo for reducing SARS-CoV-2 viral load in mild-to-moderate COVID-19 patients in primary health care

Author

Alejandro Rabanal Basalo, Mercedes Navarro Pablos, Nuria Viejo Pinero, María Luz Vila Méndez, Verónica Molina Barcena, Aránzazu Montilla Bernabé, María del Pilar Villanueva Morán, Ana María Blanco Gallego, Carmen Guirao Sánchez, Salvador Juárez Antón, Ángela Fernández Rodríguez, María Luisa Revuelta Puigdollers, María Teresa Sarriá Sánchez, Carmen Martín Alegre, Miguel Ángel Martínez Álvarez, María Mestre de Juan, Rebeca Mielgo Salvador, María Teresa Gijón Seco, José Manuel Saníger Herrera, María Esther Rodríguez Jiménez, Begoña Navas de la Peña, Javier Santa Cruz Hernández, Ana María Abad Esteban, Rebeca Díaz Martín, Laura García Pérez, Paloma Herrero Vanrell, María Isabel Arias de Saavedra Criado, Alexandra Vaquero Vinent, Verónica López Gómez, Víctor Manuel Montegrifo Rentero, Lucía Simón Miguel, Ignacio Campo Martos, Silvia Ortiz Zamorano, María Jesús Izquierdo Zamarriego, Izíar Vázquez Carrión, Rosa María López Valero, Carmen Gil, Ana Martínez, and Begoña Soler López

Subjects
SARS-CoV-2 virus, COVID-19 disease, domperidone, PCR, Medicine
Abstract

AbstractIntroduction The clinical effect of domperidone against COVID-19 has been investigated in a double-blind phase III clinical trial (EudraCT number 2021-001228-17). Domperidone has shown in vitro antiviral activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and potential immudolatory properties through the stimulation of prolactin secretion.Patients and methods The efficacy of oral domperidone plus standard of care (SOC; n = 87) versus placebo plus SOC (n = 86) was evaluated in a 28-day randomized double-blind multicentre study in primary health care centres. A total of 173 outpatients with mild-to-moderate COVID-19 were included. Three daily doses of 10 mg (30 mg/day) of domperidone or placebo were administered for 7 days. Reduction of viral load on day 4 was the primary efficay endpoint. It was estimated in saliva samples by reverse transcription-quantitative polymerase chain reaction (RT-qPCR), as the cycle thresholds detected ORF1ab, N Protein and S Protein genes.Results A significant reduction in the viral load was observed (p

Published
2023
Full Text
View/download PDF

2. Efficacy of Bromhexine versus Standard of Care in Reducing Viral Load in Patients with Mild-to-Moderate COVID-19 Disease Attended in Primary Care: A Randomized Open-Label Trial

Author

María Luz Vila Méndez, Carmen Antón Sanz, Alicia del Rocío Cárdenas García, Amparo Bravo Malo, Francisco Javier Torres Martínez, José María Martín Moros, María Real Torrijos, José Francisco Javier Vendrell Covisa, Olga Guzmán Sierra, Verónica Molina Barcena, Nuria Viejo Pinero, Carlos Fernández Díaz, Purificación Arroyo Burguillo, Ana María Blanco Gallego, Carmen Guirao Sánchez, Aránzazu Montilla Bernabé, María del Pilar Villanueva Morán, Salvador Juárez Antón, Ángela Fernández Rodríguez, María Ángeles Somoza Calvo, Ernesto Cerrada Cerrada, Gemma Pérez Mañas, Antonio Sánchez Calso, Frida Vallejo Somohano, Carmen Cauqui Díaz, Gloria Viñas Fernández, Jesús Molina París, Marina González Godoy, Gonzalo Lumbreras García, Javier Rosado Martín, Aida Rodríguez Hernández, Sara López Antúñez, Gabriel Vázquez Perfecto, María Concepción Marcello Andrés, Nieves Marina Puente García, Carmen Gil, Ana Martínez, and Begoña Soler López

Subjects
General Medicine, COVID-19, SARS-CoV-2, bromhexine, standard of care, viral load, primary care
Abstract

A 28-day randomized open-label multicenter study was conducted to assess the efficacy of bromhexine plus standard of care (SOC) (n = 98) vs. SOC alone (n = 93) in 191 outpatients with mild-to-moderate COVID-19 in the primary health care setting. Bromhexine three daily doses of 10 mL (48 mg/day) were administered for seven days. The primary efficacy endpoint was the reduction of viral load estimated as the cycle thresholds (Ct) to detect ORF1ab, N Protein, and S Protein genes by RT-qPCR in saliva samples on day 4 as compared with baseline. Ct values of the three genes increased from baseline throughout days 4 to 14 (p < 0.001) but significant differences between the study groups were not found. Differences in the percentages of patients with low, medium, and high viral loads at 4, 7, and 14 days were not found either. In summary, treatment with bromhexine plus SCO was associated with a viral load reduction of ORF1ab, N Protein, and S Protein genes at day 4, which was not significantly different than similar viral load reductions observed with SOC alone. The present findings do not seem to favor the use of bromhexine as an antiviral in patients with COVID-19.

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results